| |
| |
|
| Insider
Information: |
Frates James M |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
318,827 |
|
|
Indirect Shares
|
184,010 |
|
|
| Direct
Value |
$2,266,315 |
|
|
|
Indirect Value
|
$3,841,911 |
|
|
| Total
Shares |
502,837 |
|
|
| Total
Value |
$6,108,226 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alkermes Plc |
ALKS |
SVP, Alks Inc; CFO ALKS |
2020-05-14 |
91,828 |
2020-05-14 |
155,669 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2021-06-16 |
1,035 |
2021-06-16 |
1,810 |
Premium* |
|
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2024-04-16 |
225,964 |
2024-04-16 |
26,531 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2024-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
91,180 |
225,964 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2024-03-05 |
4 |
S |
$18.73 |
$33,560 |
D/D |
(1,792) |
134,784 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
152,035 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2024-01-09 |
4 |
S |
$16.33 |
$44,347 |
D/D |
(2,716) |
112,035 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-10-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
11,072 |
11,072 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-08-23 |
4 |
OE |
$6.88 |
$124,975 |
D/D |
18,165 |
106,341 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-05-16 |
4 |
AS |
$26.93 |
$875,451 |
D/D |
(32,500) |
55,676 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-05-16 |
4 |
OE |
$6.88 |
$223,600 |
D/D |
32,500 |
88,176 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-03-16 |
4/A |
AS |
$31.86 |
$1,036,459 |
D/D |
(32,500) |
34,009 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-03-16 |
4 |
AS |
$31.86 |
$1,036,459 |
D/D |
(32,500) |
1,509 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
21,667 |
23,176 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-03-16 |
4/A |
OE |
$6.88 |
$223,600 |
D/D |
32,500 |
66,509 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-03-16 |
4/A |
A |
$0.00 |
$0 |
D/D |
21,667 |
55,676 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2023-01-06 |
4 |
S |
$36.08 |
$96,481 |
D/D |
(2,658) |
34,009 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2022-12-30 |
4 |
OE |
$6.88 |
$34,400 |
D/D |
5,000 |
36,667 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
31,667 |
0 |
- |
|
| AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2022-01-06 |
4/A |
A |
$0.00 |
$0 |
I/I |
19,482 |
19,482 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2021-06-16 |
4 |
B |
$55.10 |
$99,735 |
I/I |
1,810 |
1,810 |
0.01 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-05-14 |
4 |
OE |
$11.74 |
$258,080 |
D/D |
21,983 |
91,828 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,500 |
71,168 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-03-01 |
4 |
D |
$20.84 |
$27,571 |
D/D |
(1,323) |
69,845 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-02-21 |
4 |
D |
$20.24 |
$34,651 |
D/D |
(1,712) |
66,668 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,825 |
68,380 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-02-17 |
4 |
D |
$17.77 |
$16,064 |
D/D |
(904) |
62,555 |
0 |
- |
|
| ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
• • – |
2020-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
63,459 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
